Loading
A phase 3 trial of Motixafortide, Filgrastim in multiple myeloma, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting.
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients is a phase 3 interventional study registered as NCT06514508 by Guangzhou Gloria Biosciences Co., Ltd., with 60 participants planned, started 2025-12-01 and due to reach its primary completion in 2026-09-11. Interventions recorded: Motixafortide+G-CSF, Placebo+G-CSF. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Motixafortide, Filgrastim (G-CSF), Multiple myeloma.
Shares Filgrastim (G-CSF), Multiple myeloma.
Shares Filgrastim (G-CSF), Multiple myeloma.
Shares Motixafortide, Filgrastim (G-CSF), Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/